The International Neoadjuvant Melanoma Consortium (INMC), of which MIA’s Professor Long is a founder with three colleagues from MD Anderson USA, has been awarded the 2025 Society for Immunotherapy of Cancer Collaboration Award for its work in pioneering neoadjuvant immunotherapy for melanoma.
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
In what has been described as a cancer treatment revolution, the pre-surgery use of combination immunotherapy looks to become standard treatment for melanoma and impact other cancers across the globe.
